Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 75 years old, of any gender
- People diagnosed with hepatocellular carcinoma (a type of liver cancer) either through standard clinical guidelines or confirmed by tissue or cell testing, with at least one tumour that is large enough to be measured on a scan (confirm with trial site for exact size requirements)
- People whose liver cancer has either not been treated with systemic (whole-body) therapy before, or whose cancer has progressed or become intolerable after first-line systemic treatment, and whose cancer cannot be surgically removed
- People whose cancer is classified as CNLC stage IIb to IIIb (a specific staging system for liver cancer — confirm with trial site)
- People whose liver function is rated as Child-Pugh grade A or B with a score of 5–7 (a measure of how well the liver is working — confirm with trial site)
- People with an ECOG performance score of 0 or 1, meaning they are fully active or have only minor restrictions on physical activity
- People with an expected survival of at least 12 weeks
- People with an active hepatitis B infection may still be considered, depending on their virus levels at the time of enrolment (confirm with trial site)
- People who are willing to participate, can follow the study requirements, and are able to attend follow-up appointments
Who may not be able to join:
- Women who are pregnant or breastfeeding
- People who have contraindications to immunotherapy, including those who have had an organ transplant, have a severe autoimmune disease, have organ failure, have previously had a severe (grade 4 or higher) reaction to immunotherapy, or have an infection that is not under control
- People who have used immunosuppressive medications or high-dose steroid therapy (above the equivalent of 10mg/day of prednisone) within the 14 days before enrolment
- People with a known allergy to the study drugs camrelizumab or apatinib mesylate, their ingredients, or other monoclonal antibody medications
- People with impaired consciousness, an inability to cooperate with treatment, or a diagnosed mental illness
- People who have participated in another clinical trial within the past three months
- People with severe failure of major organs such as the liver, kidneys, heart, lungs, or brain
- People with other serious health conditions that, in the investigator's judgment, could put them at risk or prevent them from completing the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Wu h Guo, Mengchao Hepatobiliary Hospital, Fujian Medical University
Phone: 13805083802
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free survival（PFS）
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.